AGAnirban Sen Gupta

Anirban Sen Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anirban Sen Gupta has a total of 274 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Stearyl‐Peptide Based Versatile Strategy to Design Enzyme‐Responsive Liposomes for Targeted Drug Delivery

    by Shruti Raghunathan, Norman Luc, Dante Disharoon, Sonali Rohiwal, Keren Hu, Rahul Darbhakul, Jenny Lian, Hanyang Wang, Rohini Sekar, Bipin Chakravarthy Paruchuri, et al.

    Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio‐temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next‐generation liposome designs focus on stimuli‐triggered enhancement of drug release. One exciting approach here is liposomes that can be site‐specifically destabilized by disease‐associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease‐specific enzyme remains lacking. We report a unique liposome design using enzyme‐cleavable stearyl‐peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme‐cleavable peptides to stearylamine and assembly of stearyl‐peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface‐decorating such liposomes with target‐specific ligands enables their active target‐anchorage under flow. Exposure of target‐anchored liposomes to disease‐relevant enzymes renders stearyl‐peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.

  • Open Access

    Safety and emergency dose-response evaluation of lyophilized synthetic platelets in a rat model of traumatic hemorrhage

    by Norman F. Luc, Dante Disharoon, Selvin Hernandez, Ujjal Didar Singh Sekhon, Baylee Traylor, Emily Gahagan, Emma Quill, Kristin Aldridge, Michael A. Bruckman, Christa L. Pawlowski, et al.

  • Open Access

    Lyophilized Synthetic Platelets: In Vitro Characterization and In Vivo Evaluation in Mouse Thrombocytopenia Model

    by Ujjal Didar Singh Sekhon, Dante Disharoon, Shrijal S. Desai, Baylee Traylor, Emily Gahagan, Emma Quill, Kristin Aldridge, Norman F. Luc, Sonali Rohiwal, Shruti Raghunathan, et al.

    Platelet transfusions to treat bleeding complications use donor‐derived platelets stored at room‐temperature, that have a shelf‐life of only 5–7 days due to bacterial contamination risks. Cold‐stored and freeze‐dried platelets are being investigated for extending shelf‐life, but these still have the inherent challenge of donor‐dependency. To address this, we developed a liposome‐based synthetic platelet (SP) nanoconstruct that mimics the primary hemostatic mechanisms of platelets, and have previously reported its efficacy. However, a logistical limitation of SP is its susceptibility to environment‐induced physico‐chemical instabilities that reduces shelf‐life when stored as aqueous suspension, impacting its availability and bioactivity. Lyophilization of liposomal nanotherapeutics utilizing anhydrobiosis‐inspired lyoprotectants can enhance shelf‐life, but this has not been explored for synthetic platelets. With these considerations, we report advancing SP into a lyophilized product (Lyo‐SP) that can be rapidly aqueous‐reconstituted for on‐demand use. Lyo‐SP retained morphology, size, and charge in long‐term storage at various temperatures, and conserved platelet‐mimetic functions in multiparametric assays with human plasma and blood. Lyo‐SP demonstrated biosafety in its effect analysis on endothelial cells, neutrophils, RBCs and complement C3. Lyo‐SP significantly reduced bleeding in a tail‐clip model in thrombocytopenic mice. These studies establish the potential of Lyo‐SP as a shelf‐stable platelet surrogate for treating bleeding complications.


  • Open Access

    Defining and quantifying oxygen delivery potency of blood products

    by Stephen C. Rogers, Mary Brummet, Kevin V. Tobin, Zohreh Safari, Aishwarya Anand, Daniel Bennett, Regina Adao, Elizabeth McAslan, Mette Jacobsen, Anna Parrish, et al.


  • Open Access

    PlateChek: a surface-functionalized dielectric microsensor for specific detection of platelet-related hemostatic impairment in whole blood

    by Dante Disharoon, Sina Pourang, Christopher A. Delianides, Selvin Hernandez, Calvin Abonga, Hanif Alizadeh, Emily Song, Ryan J. Summers, Matthew D. Neal, Sanjay P. Ahuja, et al.


  • Open Access

    Intraosseous administration of lyophilized synthetic platelets renders hemostatic efficacy in rat model of traumatic hemorrhage

    by Zeyu Liu, Abiha Abdullah, Zachary A. Secunda, Norman F. Luc, Lauren Jackson, Baylee Traylor, Dante Disharoon, Christa Pawlowski, Riya Sharma, Ujjal Didar Singh Sekhon, et al.


  • Open Access

    Biosynthetic blood surrogates: Current status and future opportunities

    by Dante Disharoon, Sonali Rohiwal, Selvin Hernandez, Bipin Chakravarthy Paruchuri, Rohini Sekar, Norman Luc, Anirban Sen Gupta

    Blood is a liquid connective tissue containing cellular and non‐cellular components. Blood circulation is vital to life since it transports gases and nutrients, maintains immune surveillance, promotes necessary clotting to prevent hemorrhage, and maintains oncotic pressure and body temperature. Blood transfusion is a life‐saving procedure where donor‐derived blood is administered into a patient when the patient's own blood is diseased or depleted. However, blood transfusion faces tremendous challenges due to donor shortage, limited shelf life, transfusion‐associated infection risks, and complex logistics of blood banking and transport. A robust volume of research is currently focused on resolving these issues, including pathogen reduction technologies, temperature‐reduced storage, and bioreactor‐based production of blood cells from stem cells in vitro. In parallel, significant interest has developed toward biomaterials‐based engineering of synthetic blood surrogates that can provide critical functions of blood components while circumventing the limitations of donor‐derived blood products. Here, the major efforts have focused on the design of RBC surrogates for oxygen transport and platelet surrogates for hemostatic functions, and only limited efforts have focused on WBC mimicry. Processes have also been developed to isolate plasma or coagulation factors to treat specific bleeding risks, as well as freeze‐dry or spray‐dry plasma for long‐term storage and on‐demand use. The current article will provide a comprehensive review of various blood surrogate approaches highlighting biomaterials design and applications, important challenges, and future opportunities.


  • Open Access

    Dexamethasone-loaded platelet-inspired nanoparticles improve intracortical microelectrode recording performance

    by Longshun Li, Aniya Hartzler, Dhariyat M. Menendez-Lustri, Jichu Zhang, Alex Chen, Danny V. Lam, Baylee Traylor, Emma Quill, David E. Nethery, George F. Hoeferlin, et al.

    Long-term robust intracortical microelectrode (IME) neural recording quality is negatively affected by the neuroinflammatory response following microelectrode insertion. This adversely impacts brain-machine interface (BMI) performance for patients with neurological disorders or amputations. Recent studies suggest that the leakage of blood-brain barrier (BBB) and microhemorrhage caused by IME insertions contribute to increased neuroinflammation and reduced neural recording performance. Here, we evaluated dexamethasone sodium phosphate-loaded platelet-inspired nanoparticles (DEXSPPIN) to simultaneously augment local hemostasis and serve as an implant-site targeted drug-delivery vehicle. Weekly systemic treatment or control therapy was provided to rats for 8 weeks following IME implantation, while evaluating extracellular single-unit recording performance. End-point immunohistochemistry was performed to further assess the local tissue response to the IMEs. Treatment with DEXSPPIN significantly increased the recording capabilities of IMEs compared to controls over the 8-week observation period. Immunohistochemical analyses of neuron density, activated microglia/macrophage density, astrocyte density, and BBB permeability suggested that the improved neural recording performance may be attributed to reduced neuron degeneration and neuroinflammation. Overall, we found that DEXSPPIN treatment promoted an anti-inflammatory environment that improved neuronal density and enhanced IME recording performance.


  • Open Access

    Species-specific, multifaceted venom resistance in Monodelphis domestica reveals novel physiological behavior of von Willebrand Factor under flow

    by Matthew Holding, Dante Disharoon, Laura Haynes, Bipin Chakravarthy Paruchuri, M. Hao Hao Pontius, Krista Golden, Jordan A. Shavit, Karl Desch, David Ginsburg, Anirban Sen Gupta, et al.

    Interactions between predators and prey are often characterized by strong selection pressures that shape extreme physiological adaptations. Venom resistance in large-bodied South American opossums (Clade Didelphini) is a striking example, as these marsupials prey on venomous snakes and exhibit remarkable resistance to their venom. While resistance is well documented in Didelphini, relatively little is known about venom resistance in the smaller, more diverse members of Didelphidae, which inhabit the same regions and encounter the same predators. Here, we investigate venom resistance in the small-bodied opossum, Monodelphis domestica , through multi-level physiological assays, examining responses to purified venom components and whole venom from sympatric and allopatric vipers. Our results show M. domestica resists venom-induced disruptions to blood coagulation, retains platelet function in the presence of platelet-disrupting venoms, and inhibits snake venom metalloproteinases. Unexpectedly, we find that M. domestica von Willebrand Factor (VWF) requires increased shear force to elongate, a previously unknown aspect of opossum blood physiology that may contribute to venom resistance and may have relevance to human coagulopathies. These findings expand the extent of venom resistance beyond large-bodied Didelphini, suggesting it is a widespread trait in South American marsupials and providing new insights into venom-mammal coevolution. Abstract Figure: